# Bevacizumab (glioblastoma use)

Source: https://onco.cc/drugs/bevacizumab-glioma/  
OnCo record `bevacizumab-glioma` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A blood-vessel-blocking antibody that shrinks glioblastoma on scans and reduces swelling, but has never been shown to help patients live longer.

## Summary

Accelerated approval for recurrent glioblastoma (2009, full 2017) on radiographic response. AVAglio and RTOG 0825 (2014): PFS gain in newly diagnosed disease without OS benefit; EORTC 26101 at recurrence: PFS but no OS benefit with lomustine. Valuable for steroid-sparing control of oedema and radiation necrosis. A case study in pseudo-response and the limits of imaging endpoints in glioma.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-06
- Brand: Avastin
- Modality: Monoclonal antibody (anti-VEGF)
- Mechanism: Neutralises VEGF-A; normalises vasculature and reduces contrast enhancement and oedema.
- Approvals: US 2009: Recurrent glioblastoma (accelerated; full approval 2017)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bevacizumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bevacizumab

## Connected records

- cancers: [Astrocytoma, IDH-mutant (grades 2 to 4)](https://onco.cc/cancers/idh-mutant-astrocytoma/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Oligodendroglioma, IDH-mutant and 1p/19q-codeleted](https://onco.cc/cancers/oligodendroglioma/), [Paediatric high-grade glioma (excluding diffuse midline glioma)](https://onco.cc/cancers/paediatric-high-grade-glioma/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- pathways: [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- terms: [RECIST](https://onco.cc/terms/recist/)
- trials: [- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec](https://onco.cc/trials/nct06856837/), [5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct06887218/), [5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct04689347/), [A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07585279/), [A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07750041/), [A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta](https://onco.cc/trials/nct04188145/), [A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme](https://onco.cc/trials/nct07229846/), [A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer](https://onco.cc/trials/nct07347951/), [A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC](https://onco.cc/trials/nct03303495/), [A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07737600/), [A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W](https://onco.cc/trials/nct07178717/), [Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients](https://onco.cc/trials/nct05797467/), [AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer](https://onco.cc/trials/nct07021950/), [Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors](https://onco.cc/trials/nct07551778/), [AVAglio](https://onco.cc/trials/avaglio/), [BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients](https://onco.cc/trials/nct07071844/), [Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial](https://onco.cc/trials/nct07722754/), [Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer](https://onco.cc/trials/nct06566755/), [CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer](https://onco.cc/trials/nct06881537/), [CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C](https://onco.cc/trials/nct07383285/), [CheckMate 143](https://onco.cc/trials/checkmate-143/), [Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab](https://onco.cc/trials/nct06540326/), [Combination Therapy for BRAF-V600E Metastatic CRCm](https://onco.cc/trials/nct06411600/), [Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct05171660/), [Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07389265/), [ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC](https://onco.cc/trials/nct07012954/), [Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate](https://onco.cc/trials/nct06282445/), [Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM](https://onco.cc/trials/nct07728019/), [Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct05364489/), [Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC](https://onco.cc/trials/nct06643793/), [FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat](https://onco.cc/trials/nct05727163/), [FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)](https://onco.cc/trials/nct07621497/), [FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.](https://onco.cc/trials/nct06733038/), [Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)](https://onco.cc/trials/nct07362836/), [Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer](https://onco.cc/trials/nct07051785/), [FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer](https://onco.cc/trials/nct06563986/), [Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)](https://onco.cc/trials/nct07183865/), [Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct06928584/), [Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct07007728/), [JS212 Combination Therapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07503756/), [Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer](https://onco.cc/trials/nct06192680/), [Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer](https://onco.cc/trials/nct06184698/), [Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05854498/), [LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation](https://onco.cc/trials/nct07391566/), [Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients](https://onco.cc/trials/nct06280495/), [Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)](https://onco.cc/trials/nct07134101/), [New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer](https://onco.cc/trials/nct07559760/), [Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07674732/), [Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor](https://onco.cc/trials/nct00569127/), [Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer](https://onco.cc/trials/nct06764680/), [Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer](https://onco.cc/trials/nct06341296/), [Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,](https://onco.cc/trials/nct07271355/), [PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM](https://onco.cc/trials/nct06788171/), [QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer](https://onco.cc/trials/nct07025239/), [QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC](https://onco.cc/trials/nct07009145/), [QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.](https://onco.cc/trials/nct03828227/), [Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC](https://onco.cc/trials/nct07116577/), [Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct05462613/), [ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"](https://onco.cc/trials/nct07381764/), [Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct07150247/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct06835179/), [SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer](https://onco.cc/trials/nct07535632/), [SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC](https://onco.cc/trials/nct07549399/), [Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal](https://onco.cc/trials/nct07150403/), [Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer](https://onco.cc/trials/nct06856187/), [Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer](https://onco.cc/trials/nct05806931/), [Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07819604/), [Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for](https://onco.cc/trials/nct06872606/), [Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS](https://onco.cc/trials/nct07005570/), [Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB](https://onco.cc/trials/nct04776655/), [Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu](https://onco.cc/trials/nct03635021/), [Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C](https://onco.cc/trials/nct02885753/), [TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct06293014/), [Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases](https://onco.cc/trials/nct07359456/), [Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study](https://onco.cc/trials/nct02997228/), [The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct05628038/), [The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer](https://onco.cc/trials/nct06092242/), [The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi](https://onco.cc/trials/nct07204574/), [Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer](https://onco.cc/trials/nct05007132/), [Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.](https://onco.cc/trials/nct07407465/), [Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct04094688/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)

---
JSON: https://onco.cc/api/v1/entities/bevacizumab-glioma.json